MYX ASX Week ended 24 Jul 2026

Weekly Investor Report

Mayne Pharma Group Limited · Healthcare · Medical Distribution

Latest close 2.71 AUD
-5.9% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 4.6% above the Trend Line and sits at 15.0% of its 52-week range. The latest completed week returned -5.9%, after a 5.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 30 out of 100
Latest Close 2.71 AUD 24 Jul 2026
1W Return -5.9% latest completed week
4W Return 5.4% short-term follow-through
12W Return -2.5% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 4.6% above the Trend Line and sits at 15.0% of its 52-week range. The latest completed week returned -5.9%, after a 5.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1312-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.13Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.4% over four weeks, -2.5% over 12 weeks, and -48.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.9%
4W5.4%
12W-2.5%
26W-6.6%
52W-48.4%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.16Latest activity-pressure read.
Pressure change58.8%Four-week change in activity pressure.
Leadership-22.23Latest relative-leadership reading.
RS change25.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Jun 2024 Field coverage 73% Model confidence 22%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength43/100Blend of value, momentum, and quality. Underlying universe rank 58; rank 1 is best.
Value90/100Relative valuation strength. Underlying universe rank 11; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum4/100Medium-term price momentum. Underlying universe rank 97; rank 1 is best.
Growth95/100Revenue and earnings growth. Underlying universe rank 6; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-24.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
56.3%
Gross profit retained from each unit of revenue.
Operating margin
-35.9%
Operating profit retained from revenue.
Free-cash-flow margin
-9.3%
Free cash flow generated from revenue.
Return on invested capital
-27.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
112.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
5.0%
Net share repurchases relative to market value.
Shareholder yield
5.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 26 relevant articles.

3 positive · 20 neutral · 3 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-58.3%Distance below the 52-week high.
13-week volatility6.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+12.1%Week of 17 Apr.
Worst week-10.5%Week of 15 May.
Latest week-5.9%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains7
Flat weeks0
Modest losses5
Sharp losses8
Recent vol6.2%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew4.7% / -6.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.71 AUD-5.9%2.59 AUD4.68 AUD1.16-22.23729.1KOff
17 Jul 20262.88 AUD0.3%2.60 AUD4.69 AUD1.24-18.74592.8KOff
10 Jul 20262.87 AUD4.0%2.61 AUD4.70 AUD1.09-20.06751.2KOff
3 Jul 20262.76 AUD7.4%2.62 AUD4.71 AUD0.94-24.521.5MOff
26 Jun 20262.57 AUD9.8%2.64 AUD4.72 AUD0.73-29.971.7MOff
19 Jun 20262.34 AUD-2.9%2.68 AUD4.73 AUD0.52-37.57215.8KOff
12 Jun 20262.41 AUD4.8%2.75 AUD4.74 AUD0.51-36.4789.4KOff
5 Jun 20262.30 AUD-4.2%2.83 AUD4.75 AUD0.45-39.021.4MOff
29 May 20262.40 AUD-1.2%2.92 AUD4.76 AUD0.45-38.02136.9KOff
22 May 20262.43 AUD5.2%2.98 AUD4.77 AUD0.58-37.551.1MOff
15 May 20262.31 AUD-10.5%3.10 AUD4.78 AUD0.58-41.201.3MOff
8 May 20262.58 AUD-7.2%3.23 AUD4.79 AUD0.60-36.55737.2KOff
1 May 20262.78 AUD8.2%3.34 AUD4.80 AUD0.38-33.092.3MOff
24 Apr 20262.57 AUD2.4%3.44 AUD4.81 AUD0.10-39.831.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.